ArticleBMC infectious diseases2025
Time to recovery among tuberculosis patients receiving anti-Koch's drug in Ibadan, Oyo State, Nigeria.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNigeria is ranked seventh in the world and second among African countries with the highest burden of Tuberculosis (TB). This study aims to investigate the recovery time among TB patients receiving the first line of anti-Kochs (Isoniazid, Rifampicin, Pyrazinamide and Ethambutol) drugs at Chest Hospital Jericho, Ibadan. METHODOLOGY: The study design was a facility-based retrospective cohort study that was conducted among patients on anti-Kochs drugs at a TB clinic from January 2015 to December 2019, Government Chest Hospital Jericho, Ibadan, Oyo state Nigeria. Six hundred and forty-four patient records were extracted from the hospital records. Kaplan-Meier survival method was used to describe the time to recovery, and Cox-proportional hazards model was used to determine factors associated with recovery time from TB after the use of anti-Kochs drugs. Hazard ratios (HR) and their corresponding 95% confidence intervals (CI) were reported. All analyses were conducted at a 5% level of significance.
resultsThe median survival time (ST) of patients using anti-Kochs drugs for treatment was 61 (CI:59.6-62.4) days. About 72% of the patients recovered from TB after the first two months of having the disease. Patients who were female (aHR = 1.05; CI 0.89-1.25), HIV negative (aHR = 1.03, CI: 0.80-1.34) and lived in rural area (aHR = 0.97; CI 0.83-1.14) were more likely to have a shorter time to recovery from TB compared to their respective counterparts though statistically non-significant.
conclusionThis study showed a significant recovery after the use of anti-Kochs drugs. The recovery time of the participants was 61 days, which indicated that anti-Kochs drug is very effective for TB treatment. To increase adherence, it is suggested that the policy should be changed from the required time of 6 months (180 days) to 2 months (61 days), since the drugs require them to maintain a good diet during the time of taking the drugs. This finding is useful to the National TB Control Program and the hospital authorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.